Two UK-listed drugs companies have launched plans to develop a copycat version of Glaxosmithkline’s lucrative respiratory portfolio.
Hikma Pharmaceuticals and Vectura Group have signed an agreement to commercialise generic versions of Glaxo’s Ellipta products as they target the potential $5.5 billion sales forecast for the products by 2024. The tie-up marks a deepening of the relationship between Hikma and Vectura, who are attempting to launch a version of Glaxo’s successful Advair inhaler.
Hikma was founded in Jordan in 1978 and spans more than 50 countries, selling generic, branded and injectable products. It appointed Siggi Olafsson, the former boss of Teva, an Israeli rival, as chief executive this year to revive the company, which has struggled with delays in launching a generic Advair and had repeatedly…
Want to read more?Subscribe now and get unlimited digital access on web and our smartphone and tablet apps, free for your first month.Start your free trial